Dr Reddy's Asks U.S. FDA To Bypass Blocks To Revlimid Generic
This article was originally published in PharmAsia News
Executive Summary
Dr Reddy's Laboratories of India has asked U.S. FDA to take steps to allow it to bypass normal procedures and make a generic of U.S.-based Celgene's Revlimid (lenalidomide) for treating blood cancer. DRL faces two hurdles at the U.S. agency. Celgene has refused to give Dr Reddy's samples for testing for required bioequivalence testing, and the agency also is suspending approval of any generic while it conducts a risk evaluation and mitigation strategy on Revlimid. The agency is concerned about possible birth defects if expectant mothers take the drug. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.